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Summary
Background:  Oxidized  low-density  lipoprotein  (LDL)  cholesterol  is  a  sensitive  lipid  marker  for
predicting atherosclerosis.  Ezetimibe  and  statins  are  reported  to  decrease  both  LDL  choles-
terol and  oxidized  LDL  cholesterol.  This  prospective  randomized  open-label  crossover  study
compared combination  therapy  with  atorvastatin  plus  ezetimibe  versus  high-dose  atorvastatin
monotherapy.  Changes  in  serum  lipids,  including  malondialdehyde-modiﬁed  LDL  (MDA-LDL)  as
a representative  form  of  oxidized  LDL  cholesterol,  and  glucose  metabolism  were  assessed.
Methods  and  results:  The  subjects  were  39  Japanese  patients  with  coronary  artery  disease
and type  2  diabetes  or  impaired  glucose  tolerance  who  were  taking  10  mg/day  of  atorvastatin
(30 men  and  9  women  with  a  mean  age  of  67.8  years).  They  were  randomized  to  a  group
that ﬁrst  received  add-on  ezetimibe  (10  mg/day)  or  a  group  that  ﬁrst  received  atorvastatin
monotherapy  at  a  higher  dose  of  20  mg/day.  Both  treatments  were  given  for  12  weeks  each
in a  crossover  fashion.  Add-on  ezetimibe  signiﬁcantly  decreased  MDA-LDL  (109.0  ±  31.9  mg/dl
to 87.7  ±  29.4  mg/dl,  p  =  0.0009),  while  up-titration  of  atorvastatin  did  not.  The  decrease  with
add-on ezetimibe  was  signiﬁcantly  greater  than  with  up-titration  of  atorvastatin  (p  =  0.0006).
Total cholesterol  and  LDL  cholesterol  were  signiﬁcantly  decreased  by  both  treatments,
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but  the  percent  reduction  with  add-on  ezetimibe  was  signiﬁcantly  greater  (p  <  0.05).  High-density
lipoprotein  cholesterol  was  signiﬁcantly  increased  by  both  treatments  and  there  was  no  signiﬁcant
difference between  them.  The  apolipoprotein  B/apolipoprotein  A-I  ratio  and  remnant-like  parti-
cle cholesterol  were  only  signiﬁcantly  decreased  by  add-on  ezetimibe.  Both  treatments  caused
similar elevation  of  hemoglobin  A1c.
Conclusion:  In  Japanese  patients  with  type  2  diabetes  or  impaired  glucose  tolerance  and  coronary
artery disease,  adding  ezetimibe  (10  mg/day)  to  atorvastatin  (10  mg/day)  signiﬁcantly  improved
th  atorvastatin  monotherapy  at  20  mg/day.
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wells  are  coated  with  anti-MDL-LDL  monoclonal  antibody,
which  binds  with  MDA-LDL  in  the  sample.  After  removing  all
of  the  unbound  material,  horseradish  peroxidase-labeledthe lipid  proﬁle  compared  wi
© 2011  Japanese  College  of  C
Introduction
It  is  well  known  that  the  serum  level  of  low-density  lipopro-
tein  (LDL)  cholesterol  is  the  most  signiﬁcant  risk  factor  for
coronary  artery  disease  (CAD)  [1].  In  addition,  there  is  a
close  relationship  between  a  decrease  in  LDL  cholesterol  and
an  anti-inﬂammatory  effect  [2,3]. High-dose  statin  therapy
has  these  beneﬁcial  effects,  resulting  in  the  prevention  of
cardiovascular  events  [4].
Ezetimibe  inhibits  the  uptake  of  dietary  and  biliary
cholesterol  [5].  Intensive  lipid  lowering  can  be  achieved
by  the  combination  of  a  statin  with  ezetimibe  [6],  but
it  remains  controversial  whether  such  combined  therapy
signiﬁcantly  prevents  atherosclerosis  compared  with  statin
monotherapy.  It  was  reported  that  combined  therapy  with
simvastatin  (80  mg/day)  and  ezetimibe  (10  mg/day)  does  not
signiﬁcantly  reduce  intima—media  thickness  compared  with
simvastatin  monotherapy  [7].  In  contrast,  other  studies  have
shown  that  combination  therapy  with  a  statin  and  ezetim-
ibe  signiﬁcantly  preserves  endothelial  function  after  a  fat
load  and  signiﬁcantly  prevents  inﬂammation  compared  with
high-dose  statin  monotherapy  [8,9]. Accordingly,  we  hypoth-
esized  that  the  combination  of  atorvastatin  (10  mg/day)  and
ezetimibe  (10  mg/day)  could  have  a  beneﬁcial  effect  (due
to  inhibition  of  cholesterol  absorption)  on  the  lipid  proﬁle  of
Japanese  patients  with  type  2  diabetes  or  impaired  glucose
tolerance  (IGT)  and  CAD  compared  with  high-dose  atorvas-
tatin  monotherapy  (20  mg/day).
Methods
Study  population
This  was  a  prospective,  randomized,  open-label,  clinical
trial  in  Japanese  subjects  at  the  Department  of  Cardiology
of  Anjo  Kosei  Hospital  (Anjo,  Japan),  in  which  atorvastatin
plus  ezetimibe  therapy  was  switched  to  high-dose  atorvas-
tatin  alone  or  vice  versa.  There  was  no  washout  period
between  the  two  treatments  because  of  ethical  consider-
ations.  The  ﬁrst  subject  was  enrolled  in  October  2008  and
the  last  subject  completed  the  study  in  July  2009.  Patients
eligible  for  inclusion  had  IGT  or  type  2  diabetes,  were  on
treatment  with  atorvastatin  (10  mg/day)  for  dyslipidemia,
and  had  CAD  with  angiographic  stenosis  (≥50%  diameter
stenosis  on  quantitative  coronary  angiography)  or  a  history
of  coronary  revascularization  for  stable  angina.  Exclusion
criteria  were  acute  coronary  syndrome  within  6  months,
inﬂammatory  disease,  infectious  disease,  malignancy,  a his-
tory  of  hypersensitivity  to  ezetimibe  or  atorvastatin,  severe
liver  dysfunction  or  renal  dysfunction,  and  insulin  treatment
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or diabetes.  Pregnant  women,  women  who  might  be  preg-
ant,  and  breast-feeding  women  were  also  excluded.  The
osage  of  anti-angina  agents,  antihypertensive  agents,  and
ipid-lowering  agents  was  not  changed  throughout  the  study
eriod.
A  diagnosis  of  IGT  was  based  on  a  fasting  plasma  glu-
ose  level  <126  mg/dl  and  a  2-h  plasma  glucose  level
f  140—199  mg/dl  in  the  75  g  oral  glucose  tolerance  test
OGTT),  while  diabetes  was  deﬁned  by  casual  plasma  glu-
ose  ≥200  mg/dl,  fasting  plasma  glucose  ≥126  mg/dl,  or  2-h
lasma  glucose  ≥200  mg/dl.
Eligible  patients  who  gave  written  informed  consent  were
andomly  allocated  to  two  groups  on  the  day  after  coronary
ngiography,  if  coronary  stenosis  was  conﬁrmed.  Patients
llocated  to  the  group  receiving  combination  therapy  ﬁrst
ere  initially  given  10  mg/day  of  atorvastatin  combined  with
0  mg/day  of  ezetimibe,  while  patients  allocated  to  the
roup  receiving  up-titration  of  atorvastatin  ﬁrst  were  given
0  mg/day  of  atorvastatin.  After  12  weeks,  each  regimen
as  switched  to  the  other  one  and  treatment  was  contin-
ed  for  another  12  weeks  (Fig.  1).  Subjects  attended  the
ospital  monthly  for  assessment  of  their  general  condition,
dherence  to  treatment,  and  adverse  events.  At  the  start  of
reatment  and  at  the  end  of  the  ﬁrst  and  second  treatment
eriods,  the  subjects  also  underwent  laboratory  tests.
The  study  protocol  was  approved  by  the  hospital  ethics
ommittee  and  written  informed  consent  was  obtained  from
very  patient.
aboratory  tests
enous  blood  samples  for  determination  of  serum  lipids
nd  other  laboratory  parameters  [malondialdehyde-
odiﬁed  LDL  (MDA-LDL),  total  cholesterol,  LDL  cholesterol,
igh-density  lipoprotein  (HDL)  cholesterol,  triglycerides,
polipoproteins  A-I  and  B,  and  remnant-like  particle  (RLP)
holesterol]  were  obtained  between  7:00  and  8:00  AM  on
he  day  of  the  75  g  OGTT  (baseline  data).  Serum  lipids  were
easured  by  enzymatic  methods  using  an  autoanalyzer
Hitachi  Co.,  Tokyo,  Japan)  in  the  hospital  laboratory
mmediately  after  blood  sampling.  Levels  of  MDA-LDL  were
easured  using  a  sandwich  enzyme-linked  immunosorbent
ssay  (ELISA)  (SRL  Inc.,  Tokyo,  Japan).  In  the  ELISA  kit,  testnti-apolipoprotein  B  monoclonal  antibody  is  added,  which
inds  to  the  MDA-LDL  captured  on  the  plate.  After  that,
ubstrate  solution  and  stop  reagent  are  added.  The  intensity
f  color  that  develops  is  read  by  a  microplate  reader.  The
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Table  1  Patient  characteristics  at  baseline  (n  =  39).
Parameter
Age,  years 67.8  ±  9.7
Male  gender 30 (76.9%)
Body  mass  index,  kg/m2 24.8  ±  3.4
Abdominal  circumference,  cm 89.6  ±  7.4
Metabolic  syndrome 17 (43.6%)
Current  smoker 8 (20.5%)
Hypertension 36 (92.3%)
Antihyperglycemic  drug 10 (25.6%)
Alpha-glucosidase  inhibitors 6 (15.4%)
Pioglitazone 3 (10.3%)
Sulfonylurea 3 (10.3%)
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wFigure  1  Dispo
bsorbance  is  proportional  to  the  concentration  of  MDA-
DL  in  the  sample.  Apolipoproteins  were  determined  by
xed-rate  immunonephelometry  using  a  JEOL  JCA-BM8000
JEOL  Inc.,  Tokyo,  Japan).  Plasma  RLP  cholesterol  was
etermined  with  a  JIMRO-II  assay  kit  (Otsuka  Inc.,  Tokyo,
apan)  and  a  Hitachi  autoanalyzer  7070  (Hitachi  Co.),  using
n  immunoseparation  method.
tatistical  analysis
tatistical  analysis  was  performed  using  StatView  5.0  soft-
are  (SAS  Institute  Inc.,  Cary,  NC,  USA).  Continuous
ariables  are  presented  as  the  mean  ±  standard  deviation
nd  were  compared  by  using  Student’s  t-test.  Compar-
son  of  various  parameters  among  the  baseline  values
fter  both  treatments  was  done  by  Wilcoxon’s  signed
ank  test.  Data  on  the  lipid  proﬁles  were  evaluated
y  analysis  of  variance  (ANOVA)  with  respect  to  treat-
ent  sequence,  treatment  period,  treatment  regimen,  and
atients.  Differences  between  the  two  treatment  regimens
ere  determined  by  the  paired  t-test.  In  all  analyses,
 <  0.05  was  considered  statistically  signiﬁcant.
esults
hirty-nine  patients  were  enrolled  in  the  study.  Twenty
atients  initially  received  10  mg  of  atorvastatin  combined
ith  10  mg  of  ezetimibe,  while  nineteen  patients  initially
eceived  20  mg  of  atorvastatin.  No  patient  in  either  group
ithdrew  from  treatment  during  the  follow-up  period,
lthough  2  patients  experienced  abdominal  discomfort  with-
ut  any  evidence  of  liver  dysfunction  or  diarrhea.  No
usculoskeletal  adverse  events  were  observed  and  no
atient  in  either  group  had  an  increase  in  serum  amino-
ransferases  above  the  normal  range.  Follow-up  data  were
ollected  from  all  enrolled  patients.  The  baseline  charac-
eristics  of  the  subjects  are  shown  in  Table  1.
Table  2  shows  the  levels  of  MDA-LDL,  LDL  cholesterol,  and
ther  parameters  before  and  after  treatment  with  either
ombination  therapy  or  high-dose  atorvastatin  monother-
py.  According  to  ANOVA,  there  was  no  inﬂuence  of  the
equence  and  treatment  period.  Both  treatments  produced
igniﬁcant  reduction  in  the  serum  levels  of  LDL  cholesterol
nd  total  cholesterol,  along  with  a  signiﬁcant  increase  in
DL  cholesterol.  Ezetimibe  plus  atorvastatin  achieved  a  sig-
iﬁcantly  greater  reduction  in  LDL  cholesterol  and  total
holesterol  than  up-titration  of  atorvastatin  to  20  mg/day
a
n
c
cData are presented as the mean ± SD or as numbers (percent-
ages).
p  <  0.0001).  The  increase  in  HDL  cholesterol  with  combina-
ion  therapy  was  similar  to  that  observed  with  up-titration.
eduction  in  the  serum  triglyceride  level  was  not  signiﬁcant
n  either  group.
Ezetimibe  plus  atorvastatin  signiﬁcantly  reduced  the
erum  concentration  of  MDA-LDL  from  109.0  ±  31.9  IU/l  to
7.7  ±  29.4  IU/l  (p  =  0.0009).  On  the  other  hand,  MDA-LDL
as  not  signiﬁcantly  decreased  in  the  high-dose  atorvas-
atin  group  [109.0  ±  31.9  IU/l  to  106.0  ±  34.9  IU/l  (p  =  NS)].
he  MDA-LDL  level  was  signiﬁcantly  lower  after  combination
herapy  than  after  up-titration  monotherapy  (p  =  0.0006)
Table  2 and  Fig.  2).  An  increase  in  apolipoprotein  A-I  lev-
ls  was  only  seen  in  the  subjects  receiving  combination
herapy  (p  =  0.0005  versus  baseline).  A  signiﬁcant  reduction
n  apolipoprotein  B  was  seen  in  both  groups,  but  it  was
uch  greater  in  the  combination  therapy  group  (p  =  0.0063)
Table  2  and  Fig.  3).  Only  combination  therapy  signiﬁ-
antly  reduced  the  apolipoprotein  B/apolipoprotein  A-I  ratio
p  <  0.0001  versus  baseline)  and  the  level  of  RLP  cholesterol
Table  2  and  Fig.  4).
iscussion
n  the  present  crossover  study,  both  combination  therapy
ith  atorvastatin  (10  mg/day)  plus  ezetimibe  (10  mg/day)
nd  high-dose  atorvastatin  monotherapy  (20  mg/day)  sig-
iﬁcantly  decreased  the  levels  of  total  cholesterol,  LDL
holesterol,  and  apolipoprotein  B,  while  increasing  HDL
holesterol,  compared  to  treatment  with  10  mg/day  of
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Table  2  MDA-LDL,  LDL  cholesterol,  other  lipid  parameters,  and  hemoglobin  A1c at  baseline  and  after  treatment.
Parameter  Baseline  After  combination  therapy  After  monotherapy
MDA-LDL,  IU/l  109.0  ±  31.9  87.7  ±  29.4*,† 106.0  ±  34.9
LDL cholesterol,  mg/dl  111.6  ±  16.6  82.9  ±  20.5*,† 98.4  ±  22.7*
HDL  cholesterol,  mg/dl  46.7  ±  10.2  52.8  ±  12.6* 50.0  ±  11.6*
Triglycerides,  mg/dl  124.3  ±  55.9  113.7  ±  58.6  125.7  ±  77.9
Total cholesterol,  mg/dl  178.1  ±  23.8  147.8  ±  21.3*,† 164.3  ±  25.8*
Apolipoprotein  A-I,  mg/dl 126.3  ±  19.6  133.5  ±  22.5* 126.4  ±  21.1
Apolipoprotein  B,  mg/dl 90.1 ±  12.4  73.9  ±  18.0*,† 83.7  ±  17.2*
Apolipoprotein  B/apolipoprotein  A-I  ratio 0.73 ±  0.15  0.57 ±  0.18*,† 0.68  ±  0.19
Fasting blood  glucose,  mg/dl 111.1 ±  19.0  112.5 ±  20.9  115.4 ±  30.3
Hemoglobin A1c,  %  5.70 ±  0.61  6.03 ±  0.64* 5.97 ±  0.67*
RLP-cholesterol,  mg/dl  4.40  ±  2.93  3.85  ±  2.68* 4.85  ±  4.90
Data are presented as the mean ± SD. MDA, malondialdehyde-modiﬁed; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP,
remnant-like particle.
* p < 0.05 versus baseline.
† p < 0.05 versus monotherapy group.
atorvastatin  alone.  However,  only  combination  therapy  with
atorvastatin  plus  ezetimibe  had  the  effect  of  reducing
MDA-LDL  levels  and  increasing  apolipoprotein  A-I  levels.  Pre-
vious  reports  have  shown  that  both  ezetimibe  and  statin  in
monotherapy  decrease  the  plasma  level  of  MDA-LDL  [10,11].
The  present  study  demonstrated  for  the  ﬁrst  time  that  add-
on  ezetimibe  therapy  is  more  effective  in  the  decrease  of
MDA-LDL  level  than  up-titration  statin  therapy.
The  prognosis  is  often  worse  for  patients  who  have
IGT  compared  with  subjects  who  have  normal  glucose  tol-
erance  or  impaired  fasting  glucose  [12,13].  In  patients
with  impaired  glucose  metabolism,  cholesterol  absorption
is  often  enhanced  and  postprandial  hypertriglyceridemia  is
common  [14]. Postprandial  hyperglycemia  induces  oxidative
stress,  decreases  ﬂow-mediated  vasodilatation,  and  impairs
endothelial  nitric  oxide  release  [15,16].  In  such  a  situation,
it  may  be  useful  to  investigate  oxidative  stress.  Oxidised  LDL
cholesterol  (including  MDA-LDL)  is  a  relatively  new  marker
ns
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Figure  2  Changes  in  serum  malondialdehyde-modiﬁed  low-
density  lipoprotein.
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if  oxidative  stress,  which  has  been  reported  to  be  a  stronger
redictor  of  cardiovascular  risk  than  standard  lipid  param-
ters  [17,18]. In  particular,  the  plasma  level  of  MDA-LDL
s  related  to  atherogenic  processes  such  as  foam  cell  for-
ation,  endothelial  dysfunction,  and  vascular  inﬂammation
17—19].  Although  combination  therapy  with  ezetimibe  and
 statin  has  been  shown  to  reduce  atherogenic  oxidized  LDL
holesterol  in  addition  to  lowering  LDL  cholesterol  [20], a
linical  trial  has  not  been  performed  to  investigate  the  dif-
erential  effects  of  these  drugs.  In  the  present  study,  we
nvestigated  changes  of  apolipoprotein  A-I  and  apolipopro-
ein  B.  Apolipoprotein  A-I  has  a  protective  effect  against
remature  atherosclerosis  [21,22],  while  apolipoprotein  B
nd  apolipoprotein  B/apolipoprotein  A-I  ratio  are  considered
o  be  a  better  indicator  of  atherogenic  lipoprotein  particles
han  the  LDL  cholesterol  level  or  non-HDL  cholesterol  level
22,23].  Also,  the  remnant-like  particle  cholesterol  level
an  predict  future  cardiovascular  events  [24,25]. A  previ-
us  report  has  suggested  that  the  association  between  high
evels  of  remnant  lipoprotein  cholesterol  and  high  MDA-LDL
evels  might  be  linked  to  atherogenesis  in  patients  with  coro-
ary  artery  disease  [26]. Accordingly,  our  ﬁndings  might  be
f  clinical  signiﬁcance.
In  the  current  study,  only  combination  therapy  with  ator-
astatin  plus  ezetimibe  had  the  effect  of  reducing  MDA-LDL
evels.  Some  mechanisms  are  possible  to  explain  this.  First,
zetimibe  effectively  decreased  the  uptake  of  oxidized  LDL
rom  dietary  intake.  Previous  reports  have  suggested  that
holesterol  absorption  increases  in  patients  with  diabetes,
ith  long  administration  of  statins,  and  a  history  of  coro-
ary  artery  disease  [14,27—29].  We  enrolled  these  patients
n  this  study.  Second,  ezetimibe  inhibited  the  postpran-
ial  dyslipidemia,  and  this  effect  resulted  in  the  decrease
f  atherogenic  small,  dense  LDL  and  oxidative  LDL.  Insulin
esistance  causes  postprandial  dysmetabolism,  which  causes
he  increased  oxidative  stress  and  atherogenesis  [30].
It has  been  reported  that  combined  therapy  with  eze-
imibe  plus  simvastatin  signiﬁcantly  decreases  both  serum
DL  cholesterol  and  C-reactive  protein  compared  with
imvastatin  alone  [7].  There  is  an  association  between
nﬂammation  as  indicated  by  the  C-reactive  protein  level
54  Y.  Uemura  et  al.
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nd  atherosclerosis  [31,32].  It  was  reported  that  combina-
ion  therapy  with  simvastatin  (10  mg/day)  plus  ezetimibe
10  mg/day)  for  6  weeks  preserved  postprandial  endothe-
ial  function  unlike  treatment  with  simvastatin  (80  mg/day)
lone  in  men  with  metabolic  syndrome  [9].  Thus,  combina-
ion  therapy  may  be  a  good  choice  in  subjects  with  abnormal
lucose  tolerance.
Simvastatin  was  the  statin  combined  with  ezetimibe  in
revious  large-scale  trials  [7,33]. Unfortunately,  combina-
ion  therapy  with  simvastatin  (80  mg/day)  plus  ezetimibe
10  mg/day)  was  not  shown  to  have  a  superior  effect
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Figure  4  Changes  in  apolipoprotein  (Apo)  B/Apo  A-I  ratiproteins  (Apo)  A-I  (A)  and  B  (B).
80 mg/day)  alone  [7].  In  addition,  combination  therapy
ith  simvastatin  (40  mg/day)  plus  ezetimibe  (10  mg/day)  did
ot  reduce  the  incidence  of  major  adverse  cardiac  events
n  patients  with  aortic  stenosis  [33]. On  the  other  hand,
trong  statins  such  as  atorvastatin  signiﬁcantly  increase  the
ietary  absorption  of  cholesterol  compared  with  moderate
tatins  due  to  the  signiﬁcantly  greater  decrease  in  choles-
erol  synthesis  [27]. It  has  been  reported  that  decreased
holesterol  absorption  is  associated  with  fewer  recurrent
ardiovascular  events  in  elderly  patients  [34]. Conversely,
ncreasing  cholesterol  absorption  was  related  to  recurrence
f  major  coronary  events  during  simvastatin  treatment  in  a
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o  (A)  and  remnant-like  particle  (RLP)  cholesterol  (B).
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[High  dose  statin  vs.  combination  of  statin  and  ezetimibe  in  
Finnish  subgroup  of  the  Scandinavian  study  [35]. Therefore,
it  may  be  possible  to  obtain  a  better  outcome  by  combi-
nation  therapy  with  a  statin  plus  ezetimibe  if  other  statins
including  atorvastatin  are  tested,  so  further  investigations
are  needed.
Study limitations
Several  limitations  of  this  study  should  be  discussed.  First,
this  was  a  single-centre  crossover  study  with  only  39
patients,  resulting  in  a  low  statistical  power  that  should  be
considered.  In  addition,  the  ﬁndings  of  this  study  cannot  be
extrapolated  to  the  general  population.  Third,  the  effects
noted  were  related  to  speciﬁc  drugs  and  drug  combinations.
Fourth,  a  carry-over  effect  might  exist  because  there  were
no  drug-free  periods  when  switching  arms.  Fifth,  data  on
changes  in  cardiovascular  events  should  be  collected  in  the
future  by  a  long-term  study  because  such  ﬁndings  might  have
great  clinical  importance.
Conclusion
In  Japanese  patients  with  coronary  artery  disease  and
abnormal  glucose  tolerance,  both  combination  therapy  with
atorvastatin  (10  mg/day)  plus  ezetimibe  (10  mg/day)  and
high-dose  atorvastatin  monotherapy  (20  mg/day)  signiﬁ-
cantly  decreased  total  cholesterol  and  LDL  cholesterol,
while  raising  HDL  cholesterol,  compared  with  low-dose  ator-
vastatin  monotherapy  (10  mg/day).  Combination  therapy
with  atorvastatin  plus  ezetimibe  achieved  superior  reduc-
tion  of  MDA-LDL  and  apolipoprotein  B  levels,  as  well  as  an
increase  in  apolipoprotein  A-I  levels,  compared  to  high-dose
atorvastatin  monotherapy.
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